Vinflunine
- Generic Name
- Vinflunine
- Brand Names
- Javlor
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54F2N4O8
- CAS Number
- 162652-95-1
- Unique Ingredient Identifier
- 5BF646324K
- Background
Vinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent that induces a cell cycle arrest at the G2/M phase and promotes cell death via apoptosis . Vinflunine is a microtubule inhibit...
- Indication
For use as a monotherapy in adults with advanced or transitional cell carcinoma of the urothelial tract after failure of a prior platinum-containing therapy .
- Associated Conditions
- Transitional Cell Carcinoma of the Urothelial Tract, Metastatic Transitional Cell Carcinoma of the Urothelial Tract
- Associated Therapies
- -
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2006-05-03
- Last Posted Date
- 2012-05-16
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 41
- Registration Number
- NCT00320073
- Locations
- ๐บ๐ธ
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2013-03-13
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 51
- Registration Number
- NCT00284154
- Locations
- ๐บ๐ธ
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
๐บ๐ธFlorida Cancer Specialists, Fort Myers, Florida, United States
๐บ๐ธOncology Hematology Care, Cincinnati, Ohio, United States
Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2013-08-09
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00284180
- Locations
- ๐บ๐ธ
Associates in Hematology Oncology, Chattanooga, Tennessee, United States
๐บ๐ธNortheast Alabama Regional Medical Center, Anniston, Alabama, United States
๐บ๐ธTennessee Oncology, Nashville, Tennessee, United States
A Phase II Single Arm Trial of Single-agent Vinflunine as Second-line Treatment of Advanced Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2005-11-10
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 70
- Registration Number
- NCT00251446
- Locations
- ๐บ๐ธ
Veeda Oncology, Houston, Texas, United States
Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium
- Conditions
- Interventions
- First Posted Date
- 2005-01-13
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 150
- Registration Number
- NCT00101608
- Locations
- ๐น๐ญ
Local Institution, Bangkok, Thailand
๐จ๐ฆLocal Insitution, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.